Welcome!

CRM Authors: Xenia von Wedel, Ian Khan, PR.com Newswire, Steve Mordue

News Feed Item

Algeta ASA Raises Euro 23 Million in Series A Round

Funds Support Continued Development of Alpharadin, Its Lead Cancer Therapeutic

OSLO, NORWAY -- (MARKET WIRE) -- 09/02/05 -- Algeta ASA, a therapeutics company dedicated to the development of novel anticancer agents based on alpha particle emitting radionuclides, announced today the closing of a Series A round of financing totaling NOK 185 million (Euro 23 million/US$29 million). The funds raised will support the continued development of the Company's lead product candidate, Alpharadin™, through its ongoing Phase II clinical trials and into pivotal Phase III trials as a potential new treatment for bone metastases arising from primary prostate cancer.

Alpharadin, is a novel bone-seeking experimental radiopharmaceutical based on the alpha particle emitter radium-223.

The syndicate of international investors included new investors HealthCap, Advent Venture Partners and SR One. Existing investors Selvaag Venture Capital, NorgesInvestor, Marlin Verdi AS and several smaller investors also participated in the round.

"We are very pleased to have attracted funding for our company from such an experienced, international group of investors, in addition to the continued support and commitment from our current investors. This is a strong endorsement for the company, its employees and the progress being made," says Dr. Thomas Ramdahl, CEO of Algeta. "With this strong financial base, we are now well placed to advance our lead product candidate, Alpharadin, through late-stage clinical trials towards commercialization, and to extend our development pipeline of new therapeutics based on our exciting alpha particle technology. We look forward to working with our new investors and greatly appreciate their experience and resources, which will assist our company going forward."

"Algeta's lead product candidate, Alpharadin, addresses a major market opportunity in the field of oncology. Bone metastases are a devastating consequence of the progression of certain cancers and current treatments are largely ineffective. HealthCap is very excited to be supporting the Algeta team in their efforts to develop new therapeutics that target this important unmet medical need," said Per Samuelsson, partner at HealthCap.

Concurrent with the financing, Per Samuelsson, Partner, HealthCap; Patrick Lee, General Partner, Advent Venture Partners; and Dr. Kent Gossett, Principal, SR One; will join Stein Annexstad, Managing Director, representing NorgesInvestor; Dr. Jens Petter Falck, Partner, Selvaag Venture Capital; and John Berriman, Chairman; on Algeta's Board of Directors.

Algeta was advised by BioScience Managers Limited (London, UK) during this financing round.

Notes to Editors

About Algeta ASA

Algeta ASA, headquartered in Oslo, Norway, is a private therapeutics company dedicated to the development of novel anticancer therapeutics based on alpha particle emitting radionuclides. The Company was founded in 1997 as Anticancer Therapeutic Inventions.

Algeta's lead product candidate, Alpharadin, is a novel bone-seeking experimental radiopharmaceutical based on the alpha particle emitter radium-223. Alpharadin is currently in Phase II clinical trials as a potential new treatment for bone metastases from prostate cancer.

An estimated 1.5 million patients worldwide suffer with bone metastases and there are approximately 300,000 new cases per year. Prostate and breast cancers account for more than 80% of all cases. Median survival for patients is three years and there are no effective therapies.

Alpha emitters have not until recently been a significant therapeutic modality. However, discoveries in radiochemistry and recent advances in the understanding of tumor and radiation biology led Algeta's scientific founders -- Roy Larsen and Oyvind Bruland -- to conceive how the unique features of alpha emitters, such as high potency and short range, could be exploited to create new therapeutic candidates promising unrivalled potency without unacceptable toxicities.

For more information, visit us at www.algeta.com.

For further information, please contact:
Dr. Thomas Ramdahl
CEO
Algeta ASA
+47 23 00 79 90

Mark Swallow PhD / Helena Podd
Citigate Dewe Rogerson
+44 (0)207 638 9571

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

IoT & Smart Cities Stories
IT professionals are also embracing the reality of Serverless architectures, which are critical to developing and operating real-time applications and services. Serverless is particularly important as enterprises of all sizes develop and deploy Internet of Things (IoT) initiatives. Serverless and Kubernetes are great examples of continuous, rapid pace of change in enterprise IT. They also raise a number of critical issues and questions about employee training, development processes, and opera...
This month @nodexl announced that ServerlessSUMMIT & DevOpsSUMMIT own the world's top three most influential Kubernetes domains which are more influential than LinkedIn, Twitter, YouTube, Medium, Infoworld and Microsoft combined. NodeXL is a template for Microsoft® Excel® (2007, 2010, 2013 and 2016) on Windows (XP, Vista, 7, 8, 10) that lets you enter a network edge list into a workbook, click a button, see a network graph, and get a detailed summary report, all in the familiar environment of...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
AI and machine learning disruption for Enterprises started happening in the areas such as IT operations management (ITOPs) and Cloud management and SaaS apps. In 2019 CIOs will see disruptive solutions for Cloud & Devops, AI/ML driven IT Ops and Cloud Ops. Customers want AI-driven multi-cloud operations for monitoring, detection, prevention of disruptions. Disruptions cause revenue loss, unhappy users, impacts brand reputation etc.
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
Atmosera delivers modern cloud services that maximize the advantages of cloud-based infrastructures. Offering private, hybrid, and public cloud solutions, Atmosera works closely with customers to engineer, deploy, and operate cloud architectures with advanced services that deliver strategic business outcomes. Atmosera's expertise simplifies the process of cloud transformation and our 20+ years of experience managing complex IT environments provides our customers with the confidence and trust tha...
The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. With the support of JETRO's dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get tailored market studies; and more.
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...